Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2001 August;92(4) > Minerva Medica 2001 August;92(4):245-50

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Minerva Medica 2001 August;92(4):245-50

Copyright © 2001 EDIZIONI MINERVA MEDICA

language: Italian

Treatment of visceral leishmaniasis

Foti G.


PDF


Aim of this report is to review the most important therapeutical choices in visceral leishmaniasis. The pentavalent antimonial derivatives (PAD) remain the first-line drugs despite the toxicity and the wide resistance. Among the other therapeutical options, the importance of lipid formulations of amphotericin B is emphasized; it is a valid resource for the treatment of leishmania-HIV co-infection in the European Mediterranean Countries; instead, due to the high cost, it cannot be proposed in developing Countries. Besides, the characteristics of other drugs are evaluated: pentamidine, aminosidine, miltefosine, allopurinol, ketoconazole, gamma-interferon; such options propose different validity in different geographical regions. Among these, interesting results are reported for miltefosine, both for efficacy and practicality of use. Finally, the importance of a vaccination strategy in endemic areas of developing Countries is underlined.

top of page